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Introduction
Biomarkers of disease are becoming increasingly recog-
nized as central in design of clinical trials. Biomarkers
allow us to link what “might be” as defined by in vitro
and animal model studies with what “is” happening in
disease pathogenesis. In scleroderma or systemic sclero-
sis (SSc) this is particularly important for implementing
new strategies for clinical trials and understanding
pathogenesis.
Aim
We investigated blood and skin from SSc patients utiliz-
ing microarray and proteomic approaches. Using the
results of these studies we evaluated existing and created
new animal models of SSc.
Patients and methods
Patients with diffuse cutaneous (dSSc), having typically
extensive skin fibrosis and limited cutaneous SSc (lSSc),
having less extensive skin fibrosis but occasionally suffer-
ing from the deadly complication of pulmonary arterial
hypertension (PAH) were recruited for cross-sectional
and longitudinal studies of gene expression and cytokine
levels. Identified biomarkers were correlated with clinical
data. New murine models were developed by delivery of
putative SSc mediators by subcutaneous osmotic pump.
Results
Skin from patients with dSSc showed upregulated
expression of TGFß- and IFN-regulated genes, permit-
ting development of a four-gene biomarker of skin dis-
ease correlating highly with the modified Rodnan skin
score, the current standard for measuring the extent of
skin involvement [1]. Peripheral blood mononuclear cell
mRNA expression and sera from lSSc patients with
PAH showed upregulated markers of monocyte activa-
tion: IFNGR1, IL13a1 and CCR1; and circulating mar-
kers of innate immunity: IL-6 and TNF-a; and vascular
activation/injury: vWF, VCAM-1 and VEGF [2]. Contin-
uous subcutaneous delivery of the toll-like receptor 3
ligand, poly(I:C), reproduces many of these features in
mice, including upregulated IFN- and TGFb-regulated
gene expression [3].
Conclusions
Identified biomarkers of SSc disease severity and
complications provide strong rationale for trials of
therapeutics targeting upregulated mediators. These
biomarkers also provide potential surrogate outcome
measures for clinical trials and insight into pathogenesis.
Mouse models showing immune dysregulation including
bleomycin induced skin disease, SSc-like graft-versus-
host-disease and chronic poly(I:C) stimulation place
innate immunity central in SSc-associated fibrosis [4].
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